• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


Prices delayed by at least 15 minutes | Print

Live UK pricing:

Shield Therapeutics PLC (STX)

ORD 1.5P
Sell: 4.60p|Buy: 4.80p|Change: 0 (0%)

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPPand can be used with Dividend reinvestment

This investment is listed on the Alternative Investment Market (AIM). Investments on this market can be higher risk and have lower liquidity, meaning they can be harder to buy or sell, and their prices may be more volatile. Before investing, make sure you understand the risks of investing.

Company profile

Shield Therapeutics PLC is a commercial-stage specialty pharmaceutical company that delivers ACCRUFeR/FeRACCRU (ferric maltol), a differentiated pharmaceutical product, to address the unmet need for patients suffering from iron deficiency,with or without anemia. The company has launched ACCRUFeR in the U.S. Outside of the U.S., it has licensed the rights to specialty pharmaceutical companies. FeRACCRU is commercialised in the UK, the European Union, and Canada, with marketing rights in Australia and New Zealand. The company's operating segments are: FeRACCRU, which generates the maximum revenue, and PT20. Geographically, it generates maximum revenue from the U.S., and the rest from the Netherlands, Canada, Japan, and South Korea.

Address

Northern Design Centre Studio 6
3rd Floor, Baltic Business Quarter
Newcastle
GBR
NE8 3DF

Telephone

+44 1915118500

Website

https://www.shieldtherapeutics.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Shield Therapeutics PLC Annual General Meeting for 20262027-06-18T13:00:00
Shield Therapeutics PLC Fourth Quarter Earnings Results for 20262027-04-09T00:00:00
Shield Therapeutics PLC Annual Report for 20262027-04-09T00:00:00

Previous key dates

NameKey Date
Shield Therapeutics PLC Annual General Meeting for 20252026-06-18T13:00:00
Shield Therapeutics PLC Annual Report for 20252026-04-10T00:00:00
Shield Therapeutics PLC Fourth Quarter Earnings Results for 20252026-04-09T00:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2026 AJ Bell. All rights reserved.